Vivos Therapeutics, Inc. (NASDAQ:VVOS) Receives Consensus Rating of “Hold” from Analysts

Vivos Therapeutics, Inc. (NASDAQ:VVOS) has received a consensus rating of “Hold” from the five brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $4.9167.

A number of brokerages recently weighed in on VVOS. HC Wainwright assumed coverage on shares of Vivos Therapeutics in a research note on Monday, November 17th. They set a “buy” rating and a $7.00 target price for the company. Zacks Research raised Vivos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, December 1st. Ascendiant Capital Markets cut their target price on Vivos Therapeutics from $6.50 to $5.50 and set a “buy” rating on the stock in a research report on Wednesday, December 3rd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Vivos Therapeutics in a report on Wednesday, January 21st.

Vivos Therapeutics Price Performance

Shares of NASDAQ:VVOS opened at $1.62 on Friday. Vivos Therapeutics has a one year low of $1.56 and a one year high of $7.95. The company has a debt-to-equity ratio of 3.31, a current ratio of 0.78 and a quick ratio of 0.78. The company has a market cap of $15.29 million, a price-to-earnings ratio of -0.92 and a beta of 6.89. The firm has a 50 day simple moving average of $2.05 and a 200 day simple moving average of $3.14.

Vivos Therapeutics (NASDAQ:VVOS) last issued its quarterly earnings data on Wednesday, November 19th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.04. The business had revenue of $6.78 million during the quarter, compared to analyst estimates of $4.49 million. Vivos Therapeutics had a negative net margin of 98.77% and a negative return on equity of 351.28%. Research analysts predict that Vivos Therapeutics will post -1.79 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vivos Therapeutics

A number of large investors have recently bought and sold shares of VVOS. Connective Capital Management LLC bought a new stake in Vivos Therapeutics in the third quarter valued at $620,000. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Vivos Therapeutics in the 2nd quarter valued at about $220,000. Finally, XTX Topco Ltd bought a new stake in Vivos Therapeutics in the 2nd quarter valued at about $65,000. 26.35% of the stock is currently owned by institutional investors and hedge funds.

About Vivos Therapeutics

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.